Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Halofantrine Hydrochloride

FDA-approved product (tablet, oral), marketed as Halfan.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Halofantrine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Malaria

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other antimalarials
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BX01

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Halofantrine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Halofantrine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions

    NCT00947128 · start 2004-09

    Registered record
    Registry ID
    NCT00947128
    Conditions
    Nausea; Vomiting
    Interventions
    Ondansetron HCl 24 mg Tablets (Sandoz, Inc.); Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-09
    Completion
    2004-10
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea; Vomiting
    InterventionOndansetron HCl 24 mg Tablets (Sandoz, Inc.); Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
    PhasePhase 1
    Registry statusCompleted

  • To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions

    NCT00861939 · start 2004-03

    Registered record
    Registry ID
    NCT00861939
    Conditions
    Depression
    Interventions
    Bupropion HCI 300 mg Extended-Release Tablets EON; WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-03
    Completion
    2004-04
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionBupropion HCI 300 mg Extended-Release Tablets EON; WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline
    PhasePhase 1
    Registry statusCompleted

  • Physical Exercise Versus Rosiglitazone in CAD and Prediabetes

    NCT00675740 · start 2004-01

    Registered record
    Registry ID
    NCT00675740
    Conditions
    Impaired Glucose Tolerance
    Interventions
    rosiglitazone; physical exercise; control
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-01
    Completion
    2007-02
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImpaired Glucose Tolerance
    Interventionrosiglitazone; physical exercise; control
    PhasePhase 4
    Registry statusCompleted

  • HerpeVac Trial for Young Women

    NCT00057330 · start 2003-01-14

    Registered record
    Registry ID
    NCT00057330
    Conditions
    Herpes Simplex Infection
    Interventions
    HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine; Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-01-14
    Completion
    2009-08-22
    Enrolment
    8,323

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHerpes Simplex Infection
    InterventionHSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine; Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine
    PhasePhase 3
    Registry statusCompleted

  • Sodium Stibogluconate Treatment of Leishmaniasis

    NCT00662012 · start 2002-06

    Registered record
    Registry ID
    NCT00662012
    Conditions
    Leishmaniasis
    Interventions
    Sodium Stibogluconate (SSG)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-06
    Completion
    2007-12
    Enrolment
    414

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeishmaniasis
    InterventionSodium Stibogluconate (SSG)
    PhasePhase 2
    Registry statusCompleted